Control Bionics (ASX: CBL) has registered and listed its NeuroStrip surface electromyography wearable platform with the US Food and Drug Administration as a medical device. Control Bionics expects the medical-grade credential to strengthen NeuroStrip’s positioning with advanced clinical rehabilitation providers, medical research institutions, and prospective human-computer interface and medtech development partners. The company views the FDA registration as a step towards accelerating growth across NeuroStrip’s three application areas of Performance, Rehabilitation, and Research & Data. Broader Market ReachNeuroStrip forms part of Control Bionics’ non-invasive neural-signal technology platform, which captures physiological signals including electrical activity generated by muscles and converts them into measurable outcomes. The underlying platform serves Performance, Rehabilitation, Research & Data and Assistive Communication applications, extending technology historically used in Assistive Communication into sports performance, medical research, platform partnerships, and broader human-computer interface uses.